Treatment Responses of Cognitive Function and Plasma Asymmetric Dimethylarginine to Atypical Antipsychotic in Patients With Schizophrenia

Frontiers in Psychiatry - Switzerland
doi 10.3389/fpsyt.2018.00733
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Frontiers Media SA

Related search

Antipsychotic Monotherapy and Polypharmacy in the Naturalistic Treatment of Schizophrenia With Atypical Antipsychotics

BMC Psychiatry
PsychiatryMental Health
2005English

Measurement of Treatment Adherence With Antipsychotic Agents in Patients With Schizophrenia

Neuropsychiatric Disease and Treatment
PsychiatryMental HealthBiological Psychiatry
2009English

Metabolomic Mapping of Atypical Antipsychotic Effects in Schizophrenia

Molecular Psychiatry
PsychiatryMolecular NeuroscienceMental HealthMolecular BiologyCellular
2007English

Plasma Levels of Asymmetric Dimethylarginine in Patients With Biopsy-Proven Nonalcoholic Fatty Liver Disease

Metabolism: Clinical and Experimental
EndocrinologyMetabolismDiabetes
2011English

Neuropsychologic Deficits in Schizophrenia Relation to Social Function and Effect of Antipsychotic Drug Treatment

Neuropsychopharmacology
PsychiatryMental HealthPharmacology
1996English

Plasma Asymmetric Dimethylarginine Levels in Healthy People

Folia Medica
Medicine
2011English

Chlorpromazine Versus Atypical Antipsychotic Drugs for Schizophrenia

2013English

Pharmacoeconomic Comparison of Ziprasidone With Other Atypical Oral Antipsychotic Agents in Schizophrenia

Farmeconomia. Health economics and therapeutic pathways
2011English

Retraction: ‘Effect of Blonanserin on Cognitive Function in Antipsychotic-Naïve First-Episode Schizophrenia’

Human Psychopharmacology
PsychiatryMental HealthNeurologyPharmacology
2017English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy